Prostate cancer remains one of the most prevalent malignancies affecting the male population worldwide, often posing a diagnostic and therapeutic conundrum. The medical community has long debated the merits and drawbacks of PSA screening, a method designed to detect prostate cancer in its early stages. Concerns have traditionally centered around the risks of overdiagnosis—detecting indolent cancers that may never threaten the patient’s health—and overtreatment, which can lead to serious adverse effects.

This updated review elucidates that screening 500 men with PSA tests can prevent one death from prostate cancer, reflecting a reduction of approximately two deaths per 1,000 men screened. These results stem from a particularly rigorous trial involving over 162,000 men monitored over a 23-year period, underscoring the essential role of long-term follow-up to uncover meaningful survival benefits. The evidence now provides moderate certainty that PSA screening offers a mortality advantage for men with sufficient life expectancy.

Dr. Philipp Dahm, a leading researcher from the University of Minnesota, highlights that these findings should foster informed discussions between clinicians and patients who are well-informed and have a favorable prognosis. The imperative is to weigh the benefits of early detection against potential harms, supporting shared decision-making that respects individual values and circumstances.

Importantly, the meta-analysis also exposed significant gaps regarding quality of life outcomes. Adverse effects such as complications from diagnostic biopsies, sexual dysfunction, and urinary incontinence were not systematically evaluated within the reviewed trials. Researchers emphasize that other landmark studies, including the ProtecT trial, provide critical insights into these treatment-related morbidities and must be integrated into clinical decision frameworks.

Despite the demonstrable mortality benefit, the specter of overdiagnosis looms large. Screening resulted in a 30% increase in prostate cancer diagnoses, largely due to earlier detection of tumors. For every one to two prostate cancer deaths prevented, approximately 36 additional cancers were identified per thousand men screened. Most notably, many of these detected cancers exhibit low-grade pathology, meaning they might remain asymptomatic and non-lethal throughout a patient’s life. This raises profound ethical and clinical considerations regarding unnecessary psychological distress and excessive therapeutic interventions.

Dr. Juan Franco from Heinrich Heine University Düsseldorf cautions against universal, indiscriminate screening mandates. Instead, he advocates for personalized screening strategies that thoroughly consider both the tangible benefits and the very real risks associated with overdiagnosis and overtreatment. Such an approach mandates nuanced conversations between healthcare professionals and patients, fostering decisions rooted in comprehensive understanding.

This new review extends beyond simply aggregating existing data; it benefits from prolonged follow-up periods that now elucidate mortality benefits previously obscured by shorter trial durations. The evolution of screening methodologies further augments the clinical utility of PSA testing. Incorporation of multi-modal diagnostic adjuncts such as magnetic resonance imaging (MRI) and kallikrein blood panels promises enhanced specificity, potentially diminishing unwarranted biopsies and therapy.

The advent of MRI in particular allows for superior characterization of prostate lesions, distinguishing aggressive cancers from indolent ones with greater accuracy. Combined with active surveillance protocols—a strategy to monitor low-risk cancers rather than proceed to immediate treatment—this represents a paradigm shift toward mitigating the harms traditionally associated with prostate cancer screening.

Early clinical data on these advanced screening techniques illustrate the potential to improve cancer detection rates while simultaneously reducing unnecessary invasive procedures. However, it remains too premature to definitively conclude whether these innovative methods enhance overall survival benefits or lessen adverse outcomes compared to PSA testing alone. Ongoing trials will be instrumental in answering these critical questions.

The implications of this review are profound for public health policy and clinical guidelines. Given the evolving evidence base, there is now a compelling rationale to revisit existing screening recommendations, emphasizing individualized risk assessment combined with improved diagnostic precision. This nuanced approach balances the imperative to reduce prostate cancer mortality against the ethical need to prevent overmedicalization.

The updated Cochrane review exemplifies how methodological rigor and prolonged observation periods can alter clinical perspectives, transforming once controversial screening strategies into viable options for selected populations. It also reinforces the dynamic nature of oncological research, where innovations in diagnostic tools and risk stratification continually reshape best practices.

In conclusion, PSA screening for prostate cancer is no longer a dichotomous choice but a complex decision matrix incorporating patient life expectancy, preferences, and evolving diagnostic modalities. This evidence synthesis marks an essential milestone, inviting healthcare policymakers, clinicians, and patients to engage more deeply with the personalized dimensions of cancer screening and prevention.

Subject of Research: People
Article Title: Prostate-specific antigen (PSA) test for prostate cancer screening
News Publication Date: 14-May-2026
Web References: DOI 10.1002/14651858.CD004720.pub4
Image Credits: Peter Homer, Creative Content Producer at Cochrane
Keywords: Prostate cancer, Cancer, Cancer screening, Oncology, Urology, Mortality rates, Morbidity, Life expectancy, Clinical trials

A recent publication featured a compelling response from Bilen, Lowentritt, Khilfeh, and colleagues, who tackle the intricacies surrounding patient outcomes between these two treatment methodologies. Their response to a letter to the editor on the subject demonstrates the depth of analysis required when evaluating treatment efficacy. This correspondence comes amid growing scrutiny and excitement within the oncology field over therapeutic strategies that could either maximize patient survival or lead to new paradigms in treatment approaches.

At its core, the comparative analysis hinges on clinical endpoints that define success in cancer treatment: progression-free survival, overall survival, and quality of life metrics. Both apalutamide and enzalutamide have been shown to prolong life by delaying cancer progression. However, the nuances of how each drug achieves this highlight crucial differences in mechanisms of action that warrant further exploration.

Apalutamide operates as a potent androgen receptor inhibitor, effectively obstructing testosterone’s ability to fuel cancer cell growth. Its relatively recent approval for metastatic castration-sensitive prostate cancer marks a significant milestone in the therapeutic landscape. Conversely, enzalutamide, another established androgen receptor antagonist, also blocks androgen signaling but does so in a slightly different manner, providing patients with an alternative pathway to find effective treatment.

As Bilen and colleagues articulate, understanding the implications of these differences is paramount in guiding treatment decisions. They note that a merely superficial comparison of survival statistics may obscure underlying variances in patient responses. The insight shared through their correspondence calls for a diligent examination of the data, highlighting the need for comprehensive analyses that go beyond standard metrics to include the diverse patient populations affected by these treatments.

Furthermore, Bilen et al. emphasize that ongoing clinical trials are crucial for elucidating these distinctions. They underscore how real-world evidence can either reinforce or challenge current assumptions, ultimately shaping patient management strategies and influencing future research funding priorities. As they navigate through the complexities of conflicting data, their response serves as a clarion call to clinicians and researchers alike: to deepen their understanding rather than merely accept prevailing narratives.

The letter also highlights concerns over the potential for bias in interpretations of trial data, expressing that not all studies are designed equally. Statistical significance, while essential, does not tell the entire story; thus, thorough scrutiny of methodology, study populations, and treatment adherence rates becomes essential in forming a consensus. As advocates for rigorous scientific inquiry, the authors underscore their commitment to enhancing patient care through advocacy for robust clinical evaluation standards.

Another crucial point raised in the correspondence is the growing collection of patient-reported outcomes, which adds a vital dimension to treatment evaluation. Patients’ experiences with drug tolerance, side effects, and overall wellbeing can markedly influence treatment trajectories. Bilen and his co-authors stress that incorporating these narratives into the clinical decision-making process can bridge the gap between data-driven protocols and individualized patient care.

Moreover, the future of metastatic castration-sensitive prostate cancer therapy may hinge on an integrated approach encompassing both pharmacologic and non-pharmacologic interventions. Bilen et al. advocate for holistic methodologies that leverage the strengths of nutritional science, psychosocial support, and innovative therapies alongside traditional drug regimens. This can unleash the potential for more comprehensive patient management strategies, aiming for synergistic effects that enhance life quality while pursuing longevity.

As we embark on this journey of nuanced understanding, it is paramount that the dialogue encompassing apalutamide versus enzalutamide continues unabated. The conversation must extend beyond academic confines to engage active participation from patients, caregivers, and health systems, transforming research into actionable insights. In doing so, we can revolutionize prostate cancer management, breathing new life into treatment strategies and clinical practice.

In conclusion, the spirited exchange initiated by Bilen, Lowentritt, Khilfeh, and Khilfeh serves as both a reminder and a tour de force that rigorous scientific discourse is vital for the advancement of oncology. The investigation into the raised issues surrounding apalutamide and enzalutamide illuminates the multifaceted nature of cancer treatment, highlighting that the quest for improved survival is as much about data as it is about patient perspectives. As this debate continues to unfold, the ultimate beneficiaries will undoubtedly be the patients who navigate these complex choices in their fight against prostate cancer.

Ultimately, one can draw the insight that navigating drug choices in the face of metastatic castration-sensitive prostate cancer should not be a quest to identify the superior drug but rather to develop a treatment paradigm that is robust, personalized, and patient-centered. The key will lie in harnessing the knowledge gained from ongoing studies and leveraging patient experiences to drive the next generation of prostate cancer therapies.

Subject of Research: Comparative effectiveness of apalutamide vs. enzalutamide in metastatic castration-sensitive prostate cancer.

Article Title: Response to Letter to the Editor Regarding: ‘Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer’.

Article References:
Bilen, M.A., Lowentritt, B., Khilfeh, I. et al. Response to Letter to the Editor Regarding: ‘Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer’. Adv Ther (2025). https://doi.org/10.1007/s12325-025-03436-9

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12325-025-03436-9

Keywords: prostate cancer, apalutamide, enzalutamide, overall survival, metastatic castration-sensitive prostate cancer, clinical trials, patient-reported outcomes, cancer treatment strategies.

What was particularly groundbreaking about docetaxel was its mechanism of action. Unlike traditional therapies that focus primarily on hormone levels, taxanes work by disrupting the microtubule network within cancer cells, which is crucial for their division and replication. As a result, they effectively halt the proliferation of cancer cells, leading to increased apoptosis or programmed cell death. The application of taxanes in clinical practice has since evolved, further underscoring their integral role in managing prostate cancer.

Recent studies have provided compelling evidence that taxanes like docetaxel do not just offer benefits in late-stage prostate cancer but are also advantageous when combined with androgen-receptor-targeting therapies in early-stage metastatic hormonally sensitive prostate cancer. This combination has been shown to enhance overall survival rates significantly, leading to a consensus among oncologists that taxane therapy should be a cornerstone of treatment regimens for prostate cancer patients across different stages of the disease.

Moreover, current research indicates that taxane therapy is well-tolerated by many patients, often displaying a manageable side effect profile. This tolerance contributes to the increasing popularity and utilization of taxanes in clinical settings, as healthcare providers feel more confident prescribing them as part of a comprehensive treatment plan for prostate cancer. Understanding patient perspectives and outcomes, particularly in terms of quality of life, adds another layer to the ongoing discussion around the use of taxanes in therapeutic strategies.

However, the introduction of taxanes into the treatment arsenal for prostate cancer is not without challenges. Resistance to these agents is a growing concern, and studies have begun to unravel the complexities of how prostate cancer cells develop resistance to taxane therapy. Some insights point to genetic mutations, alternative signaling pathways, and changes in drug metabolism as potential mechanisms contributing to this resistance. Understanding these pathways is pivotal for the development of next-generation therapies that could either enhance sensitivity to taxanes or circumvent the resistance altogether.

In navigating the future of prostate cancer treatment, the research community is at a critical juncture. Efforts are underway to exploit the mechanisms of taxane resistance to devise innovative treatment strategies. Combinations of taxanes with other modalities or the development of novel agents that target resistance pathways are being explored. A multifaceted approach is crucial, as it allows clinicians to personalize treatment, potentially improving outcomes for patients who have exhausted standard therapeutic options.

The robust body of literature surrounding taxane therapy in prostate cancer continues to evolve. Recent publications emphasize the importance of ongoing clinical trials assessing the effectiveness of new combination regimens involving taxanes. Researchers are keenly interested in understanding how these combinations can provide synergistic effects that not only improve survival but also mitigate adverse effects. The anticipation surrounding these findings is palpable among both oncologists and patients striving for better treatment outcomes.

As advancements unfold, the medical community remains vigilant in monitoring emerging evidence regarding the efficacy of taxanes in various contexts. The paradigm shift initiated by this groundbreaking therapy remains a topic of wide interest, driving ongoing discussions about best practices in oncology. The narrative of taxane therapy is far from over; indeed, it may serve as a critical reference point for the development of future cancer therapies.

In summary, the past two decades have witnessed significant progress in the understanding and application of taxanes in prostate cancer treatment. While challenges such as drug resistance continue to pose hurdles, the potential for new strategies to enhance the effectiveness of taxanes provides exciting prospects for patients and clinicians alike. The legacy of twenty years of taxane therapy not only underscores its impact on survival but also paves the way for innovations that could further transform prostate cancer care for future generations.

As we look to the future, collaborative efforts between researchers, clinicians, and pharmaceutical companies will be essential in refining treatment protocols and tackling the challenges of drug resistance. Together, the triumphs and trials of taxane therapy serve as a reminder of the ongoing quest for improved cancer therapies and the unwavering commitment to enhance patient outcomes.

By fostering a robust dialogue through clinical trials and research publications, the foundation laid by taxane therapy continues to inspire future investigations in the field. The next chapter of cancer therapy is likely to build upon these achievements, aiming for greater precision in treatment that addresses the unique intricacies of each patient’s cancer journey.

Subject of Research: The role of taxanes in the treatment of prostate cancer.

Article Title: 20 years of taxane therapy in prostate cancer — the past, present and future.

Article References:

Carceles-Cordon, M., Rodriguez-Bravo, V., Petrylak, D.P. et al. 20 years of taxane therapy in prostate cancer — the past, present and future.
Nat Rev Urol (2025). https://doi.org/10.1038/s41585-025-01104-9

Image Credits: AI Generated

DOI:

Keywords: Prostate cancer, Taxane therapy, Docetaxel, Drug resistance, Survival rates, Clinical trials.

Prostate cancer, a leading cause of cancer-related deaths among men, often presents challenges in terms of treatment resistance and disease progression. Traditional therapies, including hormone treatment and chemotherapy, although effective to some extent, frequently fail in advanced stages of the disease. This underscores the necessity for novel approaches that not only target tumors more effectively but also harness the immune system’s potential to fight cancer cells.

The review meticulously evaluates existing literature on treatment combinations that incorporate radiotherapy and radionuclides to boost the effects of immunotherapy. Radiotherapy has long been a cornerstone in cancer treatment, using high-energy radiation to destroy cancer cells. When paired with immunotherapy, which seeks to activate the body’s immune response against tumors, the potential synergies could lead to enhanced anti-tumor effects and improved patient outcomes.

Current immunotherapy strategies, such as checkpoint inhibitors, have revolutionized cancer treatment by essentially allowing the immune system to recognize and attack cancer cells more effectively. However, the challenge remains that not all patients respond to immunotherapies, which brings into question how their efficacy can be maximized. The systematic review explores various modalities that leverage radiotherapy’s ability to induce immunogenic cell death, subsequently heightening the immune response against the remaining tumor cells.

Interestingly, research has revealed that radiotherapy may also modulate the tumor microenvironment, making it more conducive for immune cell infiltration. This phenomenon is pivotal as it can lead to a domino effect where the immune system is not only stimulating an attack on the localized tumor but also orchestrating a systemic response that could prevent metastasis. Such insights bolster the rationale behind combining these treatment approaches, as detailed in the review.

Moreover, radionuclide therapy, which utilizes radioactive substances to target cancer cells, showcases a similar promise. By delivering localized radiation directly to the tumor with minimal impact on surrounding healthy tissues, this treatment can create a favorable condition for immunotherapy. The systematic review highlights notable studies indicating that radionuclide therapy can inhibit tumor growth while simultaneously enhancing the immune system’s ability to destroy cancer cells.

Fascinatingly, the review uncovers a variety of treatment protocols that have emerged from experimental studies, including the timing and dosage of these combinations, an essential factor in achieving maximum efficacy. The researchers emphasize that these protocols need to be tailored to individual patient profiles, considering aspects such as tumor type, genetic markers, and overall health condition to ensure the best possible outcomes.

However, it is important to note the potential side effects associated with these combined therapies. While radiotherapy and radionuclide treatments may significantly improve therapeutic results, they can also lead to unwanted adverse effects such as fatigue, skin reactions, and, in some cases, complications related to immune response. The systematic review discusses the fine balance between maximizing efficacy and minimizing harm, urging further research into approaches that optimize patient quality of life while enhancing treatment effectiveness.

As cancer therapies continue to advance, the implementation of personalized medicine becomes increasingly relevant. The systematic review heralds a new era wherein each therapeutic strategy is customized based on the unique biological characteristics of the cancer and the patient. This patient-centered approach could elucidate the best combinations of treatments to catalyze improved responses and reduce unnecessary exposures to less effective therapies.

In conclusion, the systematic review by Roberto et al. is a testament to the evolving landscape of cancer treatment, particularly advanced prostate cancer. By intertwining traditional radiotherapy and radionuclide therapy with cutting-edge immunotherapy, there exists immense potential to enhance therapeutic efficacy and improve patient outcomes. The insights presented in this review not only ignite hope for overcoming treatment resistance but also set the stage for future research endeavors that will shape cancer therapy in the years to come.

The continuous exploration of such treatment combinations represents a pivotal step toward understanding and combating prostate cancer more effectively. With ongoing clinical trials and research dedicated to this multifaceted approach, the medical community is poised to unlock new avenues for therapies that offer lasting solutions for patients battling this formidable disease.

The journey of understanding how best to utilize these combined approaches is still ongoing, yet the fruits of this research may very well alter the trajectory of prostate cancer treatment in ways previously deemed unthinkable. With each new study, we draw closer to a future where prostate cancer, and indeed many forms of cancer, can be managed with unprecedented effectiveness and precision.

The significance of collaborative efforts in research cannot be overstated, as multidisciplinary teams work hand-in-hand to translate findings from bench to bedside. The synthesis of clinical insights and innovative research will undoubtedly foster the next wave of breakthroughs in oncology.

As the cancer treatment landscape continues to evolve, one thing is clear: the collaboration of established therapies with immune-based strategies could redefine the standards of care and elevate the prospects of survival for patients grappling with advanced stages of prostate cancer.

In light of these advancements, advocacy for further funding and support for research initiatives remains crucial. The more we invest in understanding the complexities of cancer and the myriad interactions between treatments, the closer we will be to discovering effective solutions that could save lives and bring hope to countless patients and their families.

Overall, the horizon for prostate cancer therapy is rapidly expanding, and as new studies emerge, we remain optimistic about making strides that mark a significant departure from the conventional paradigms of cancer treatment which have long restricted the possibilities for patients.

In this age of precision medicine, where treatments can be tailored to individuals’ specific needs, the future holds promise for revolutionary methodologies that might not just control advanced prostate cancer but potentially convert it into a manageable chronic condition.

In summary, this systematic review emphasizes the critical intersection of radiotherapy, radionuclides, and immunotherapy, suggesting that the fusion of these modalities holds the potential to enhance therapeutic outcomes for prostate cancer patients, ensuring that hope is never lost in the battle against cancer.

Subject of Research: Advanced Prostate Cancer Treatment Strategies

Article Title: Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review

Article References:

Roberto, R., Stefano, S., Marco, B. et al. Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review. J Cancer Res Clin Oncol 151, 195 (2025). https://doi.org/10.1007/s00432-025-06245-3

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06245-3

Keywords: Prostate Cancer, Radiotherapy, Radionuclides, Immunotherapy, Cancer Treatment, Systematic Review

Prostate cancer remains the most commonly diagnosed cancer among men worldwide, yet its manifestation and progression display marked disparities based on racial and ethnic backgrounds. Dr. Hui Li of UVA’s Department of Pathology emphasizes that more than 70% of Asian prostate cancer patients are diagnosed at intermediate or advanced stages, which correlates with aggressive disease features such as metastasis and resistance to conventional therapies. This late diagnosis contributes to an alarmingly low five-year survival rate under 30%, starkly contrasting with statistics from Europe and North America.

Central to the team’s inquiry is the role of chimeric RNA—fusion molecules composed of transcripts from two or more distinct genes. While present in both healthy and malignant cells, their aberrant expressions in cancer have been implicated in tumor initiation, progression, and immune evasion. These molecules can modify the tumor microenvironment by either producing oncogenic proteins or reshaping gene regulatory networks that fuel cancer growth. The intricate network of chimeric RNA within prostate tumors offers a wealth of untapped biomarkers and potential druggable targets.

Leveraging data from extensive genomic databases, including the Cancer Genome Atlas and the Chinese Prostate Cancer Genome and Epigenome Atlas, the research team conducted a comparative analysis focused on Chinese patient cohorts. Their results reveal a distinctive profile of chimeric RNAs across various cell types within the tumor microenvironment—ranging from cancerous epithelial cells to immune components like macrophages and T cells. This multifaceted expression pattern underscores the complexity of prostate cancer biology and highlights the necessity for population-specific studies.

Intriguingly, the unique chimeric RNA signatures found in Chinese men were shown to modulate not only the intrinsic tumor cell behavior but also the stromal cells surrounding the tumor, which play a crucial role in cancer development and metastasis. The stromal niche, constituted by fibroblasts, immune cells, and extracellular matrix components, can significantly influence tumor aggressiveness and therapeutic resistance by facilitating cellular crosstalk and altering local biochemical signals.

Dr. Li articulates the significance of this study as the first-ever to conduct a detailed cellular and molecular comparison of chimeric RNAs between different ethnic prostate cancer populations. This approach moves beyond traditional genetic studies that often overlook tumor heterogeneity and the contributory role of the tumor microenvironment. By elucidating the population-specific chimeric RNA landscapes, the research paves a strategic path towards more individualized cancer therapies.

The implications of these findings are profound. Targeted modulation of chimeric RNAs specific to ethnic groups holds the promise to enhance the efficacy of existing treatments and overcome the barriers posed by metastasis and drug resistance. Rational drug design could harness these RNA variants as biomarkers to stratify patients for personalized therapeutic regimens, potentially improving prognosis and reducing the treatment disparities that currently exist.

Moreover, since chimeric RNA abnormalities are not confined to prostate cancer alone but are prevalent across diverse cancer types, this research may herald a broader paradigm shift in oncology. The methodology employed in this study can be extrapolated to other malignancies, providing a novel framework for cancer precision medicine that integrates population genetics and molecular profiling.

In pursuit of these advances, the researchers robustly validated over a hundred chimeric RNAs—the largest comprehensive catalog to date—several of which exhibited strong diagnostic and prognostic capacities. These molecules offer dual utility: as circulating biomarkers to monitor disease progression and as drug targets that disrupt cancer-specific signaling pathways. By revealing the “hidden repertoire” of these chimeric transcripts, the study empowers clinicians with new molecular tools to confront prostate cancer more effectively.

The team’s work, published in the open-access journal iMeta, composes a crucial scientific resource for the global research community. The collaboration involved an international cohort of scientists, reflecting the multidisciplinary and collaborative nature essential for tackling such a complex disease. Despite the enormous potential, the authors stress the necessity for similar investigations across diverse populations, urging an expansion of genomic and transcriptomic studies worldwide.

This pioneering study enriches our understanding of the molecular underpinnings of prostate cancer, especially within Asian populations that have historically been underrepresented in cancer genomics research. By illuminating the distinct chimeric RNA profiles and their functional consequences in the tumor ecosystem, the work offers hope for narrowing racial disparities in cancer outcomes. As precision medicine continues to evolve, integrating ethnicity-specific molecular information stands as an imperative step toward truly personalized cancer care.

Future research inspired by these findings may explore therapeutic agents designed to specifically disrupt pathological chimeric RNAs or reinstate normal cellular communications within the tumor microenvironment. Such approaches could enhance treatment responses and overcome obstacles related to tumor heterogeneity and immune suppression. Additionally, extending this research to explore chimeric RNA dynamics longitudinally through disease progression or treatment could provide critical insights for adaptive therapeutic strategies.

Ultimately, this transformative research not only deepens the biological understanding of prostate cancer across populations but also creates pathways for next-generation treatments that are equitable, precise, and empirically grounded in genetic evidence. With a clear roadmap for further inquiry and validation, the study stands as a landmark contribution that will likely influence clinical oncology and translational medicine for years to come.

Subject of Research: Prostate cancer, chimeric RNA, population genetics, precision medicine, tumor microenvironment

Article Title: Prostate Cancer’s Chimeric RNA Landscape: A Pathway to Tailored Treatments for Diverse Populations

Web References:
https://doi.org/10.1002/imt2.70014
http://makingofmedicine.virginia.edu/

References:
Published in iMeta, DOI: 10.1002/imt2.70014

Image Credits: UVA Cancer Center

Keywords: Prostate cancer, Chimeric RNA, Molecular genetics, Cancer treatments, Gene targeting, Tumor microenvironment, Population genetics, Cancer research, Biomarkers, Precision medicine